Newlink Genetics Corporation
(NASDAQ : NLNK)

( )
NLNK PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.44%185.971.2%$605.33m
CELGCelgene Corporation
0.00%78.801.2%$532.62m
GILDGilead Sciences, Inc.
-0.56%70.670.9%$515.72m
BIIBBiogen Inc.
0.00%296.041.2%$437.32m
NKTRNektar Therapeutics
0.00%52.855.6%$412.99m
SRPTSarepta Therapeutics, Inc.
1.73%142.7516.6%$362.52m
VRTXVertex Pharmaceuticals Incorporated
0.00%159.191.9%$269.27m
REGNRegeneron Pharmaceuticals, Inc.
0.00%331.972.6%$248.01m
ILMNIllumina, Inc.
0.00%282.653.5%$212.82m
BLUEBluebird Bio, Inc.
-0.53%168.0015.7%$193.26m
EXASExact Sciences Corporation
0.00%66.3325.4%$180.98m
AAgilent Technologies, Inc.
0.00%62.791.5%$178.44m
ALXNAlexion Pharmaceuticals, Inc.
0.00%127.572.0%$159.93m
BMRNBioMarin Pharmaceutical Inc.
0.00%99.034.4%$141.99m
INCYIncyte Corporation
0.00%74.032.5%$133.28m

Company Profile

NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA.